Letermovir as a Rescue Therapy in Kidney Transplant Recipients with Valganciclovir/Ganciclovir Refractory/Resistant Cmv Disease

被引：0
|
作者：
von Hoerschelmann, E. [1 ]
Gao, L. [1 ]
Luecht, C. [1 ]
Muench, J. [1 ]
Naik, M. G. [1 ]
Schmidt, D. [1 ]
Weber, U. [1 ]
Choi, M. [1 ]
Halleck, F. [1 ]
Budde, K. [1 ]
机构：
[1] Charite, Nephrol, Berlin, Germany
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
D130
引用
收藏
页码：S1118 / S1118
页数：1
相关论文
共 50 条
  • [41] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial
    不详
    TRANSPLANTATION, 2023, 107 (12) : 2448 - 2448
  • [42] Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis
    Helantera, I.
    Kyllonen, L.
    Lautenschlager, I.
    Salmela, K.
    Koskinen, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (09) : 2026 - 2032
  • [43] Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis
    Strizki, Julie M.
    Diamond, Tracy L.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Wang, Weiwen
    Stauffer, Nicole
    Haber, Barbara A.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (06): : e1287 - e1298
  • [44] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients A Randomized Clinical Trial
    Limaye, Ajit P.
    Budde, Klemens
    Humar, Atul
    Vincenti, Flavio
    Kuypers, Dirk R. J.
    Carroll, Robert P.
    Stauffer, Nicole
    Murata, Yoshihiko
    Strizki, Julie M.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Haber, Barbara A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (01): : 33 - 42
  • [45] Experience with belatacept rescue therapy in kidney transplant recipients
    Brakemeier, Susanne
    Kannenkeril, Dennis
    Duerr, Michael
    Braun, Tobias
    Bachmann, Friederike
    Schmidt, Danilo
    Wiesener, Michael
    Budde, Klemens
    TRANSPLANT INTERNATIONAL, 2016, 29 (11) : 1184 - 1195
  • [46] Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    Asberg, A.
    Humar, A.
    Rollag, H.
    Jardine, A. G.
    Mouas, H.
    Pescovitz, M. D.
    Sgarabotto, D.
    Tuncer, M.
    Noronha, I. L.
    Hartmann, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) : 2106 - 2113
  • [47] Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients
    Asberg, Anders
    Rollag, Halvor
    Hartmann, Anders
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1159 - 1166
  • [48] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [49] Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
    Pescovitz, MD
    Rabkin, J
    Merion, RM
    Paya, CV
    Pirsch, J
    Freeman, RB
    O'Grady, J
    Robinson, C
    To, Z
    Wren, K
    Banken, L
    Buhles, W
    Brown, F
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) : 2811 - 2815
  • [50] Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    Luan, F. L.
    Chopra, P.
    Park, J.
    Norman, S.
    Cibrik, D.
    Ojo, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3673 - 3675
12345